IDT Australia Limited · ASX:IDT
IDT Australia — Investor Presentation (April 2016)
19 slides from IDT Australia's investor presentation, Apr 13, 2016
Slide 1: IDT Good Medicine
iat GOOD MEDICINE
Slide 2: Specialty Generic Drugs, Contract Manufacturing, Contract Clinical Services
Specialty Generic Drugs Contract Manufacturing Contract Clinical Services
Slide 3: Update 13APR16: FDA Approval of Temozolomide
UPDATE 13APR16 FDA APPROVAL of TEMOZOLOMIDE • IDT’s first proprietary generic product • First in a portfolio of 24 approved US specialty generic drugs • USD200m market opportunity • Distribution via Mayne Pharma • Fundamental and transformational change to the IDT strategy, business and prospects
Slide 4: Investment Proposition
IDT AUSTRALIA LTD (ASX.IDT) INVESTMENT PROPOSITION The Business: US FDA approved generic drug portfolio Aggregate Addressable Two in-house products, one FDA approved Market over US$750m Growing contract drug development revenues Growing contract drug manufacturing revenues Growing clinical trial rev
Slide 5: A Platform for Rapid Growth
35 YEAR HISTORY A PLATFORM FOR RAPID GROWTH IDT Service Business: IDT Specialty Generics: Provides revenues and capabilities Leverages facilities and multiplies margins Drug development services revenues Revenue Step Change via Proprietary IDT Generic Contract drug Drug Portfolio manufacture revenue
Slide 6: 24 Approved US Generic Drugs
IDT SPECIALTY DRUG PORTFOLIO 24 APPROVED US GENERIC DRUGS • Purchased Dec14, now being moved into IDT facility and first batches manufactured • Recently established partnership with ANI Pharma. (Nasdaq: ANIP) to commercialize first 18 • Addressable market of USD500m+ (Jun15 IMS*) • In addition to an
Slide 7: IDT Portfolio Overview
IDT PORTFOLIO OVERVIEW US Priority Product Sales Product Priority Manufacturer Distributor (USD, 2015) Aminophylline 3 ANI Carbidopa & 1 Wellspring ANI 65.2 Levodopa Ciprofloxacin 2 IDT ANI 44.5 Clarithromycin 2 Wellspring ANI 16.2 Dexamethasone 3 ANI Dextroamphetam 3 ANI ine Diflunisal 1 Wellspring
Slide 8: IDT Portfolio Overview
IDT PORTFOLIO OVERVIEW Priority US Product Sales Product Priority Manufacturer Distributor (USD, 2015) Leucovorin 1 IDT ANI 1.4 Methoxsalen 2 IDT ANI Mexiletine 1 Wellspring ANI 11.6 Nefazodone 1 ANI 13.5 Nortriptyline 2 Wellspring ANI 24.6 Pindolol 1 Wellspring ANI 10.0 Prazosin 1 Wellspring ANI 42
Slide 9: Portfolio Snapshot as at 13Apr16
PORTFOLIO SNAPSHOT as at 13Apr16 Temozolomide Marketing Development Manufactured Stability FDA Review Approval Doxazosin Development Manufactured Stability Leucovorin Development Manufactured Pindolol Development Thiotepa Development www.idtaus.com.au 9
Slide 10: World Class Manufacturing Facilities
GLOBALLYAPPROVED WORLD CLASS MANUFACTURING FACILITIES SENSITIZING DRUGS ANTI–CANCER DRUGS HORMONES CARBOHYDRATE DRUGS HIGH CONTAINMENT TABS/CAPS HIGH CONTAINMENT TAB COATING www.idtaus.com.au 10
Slide 11: Our Clinical Unit: CMAX
CMAX OUR CLINICAL UNIT CMAX clinical trials facility, Adelaide Australia’s oldest, largest, most experienced clinical trials unit 13,000 patient, well categorised database Brand new 50 bed clinical unit located opp Royal Adelaide Hospital Global client list with large amount of repeat business Stron
Slide 12: Building an IDT Speciality Generic Portfolio
BUILDING AN IDT SPECIALITY GENERIC PORTFOLIO $$ MARGIN WITHIN VALUE CHAIN IDT REGISTRATION & SUPPLY DISTRIBUTOR IDT’s 2% API margin share WHOLESALER Generics margin up to 50 - 60% Example: PROJECT TETON: IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncol
Slide 13: Higher Returns for IDT
GOOD MEDICINE & HIGHER RETURNS FOR IDT SELL MORE EXISTING PRODUCTS EXTRACT MORE PROFITS • High fixed costs = operational leverage. • Extract more profits from those products to • As a result, profits will rise faster than improve our share of the value chain. revenues past breakeven point. • Move to
Slide 14: Highlights of the Past Year
HIGHLIGHTS OF THE PAST YEAR DEPLOYMENT OF GENERIC US DRUG PORTFOLIO ANI Pharma and Mayne Pharma appointed to distribute in US More manufacturing resources brought to bear on return to market BUILDING IN-HOUSE DRUG PORTFOLIO Filed first IDT ANDA for temozolomide November 13 (USD200m opportunity) Appr
Slide 15: Board & Management in Place to Deliver
BOARD & MANAGEMENT IN PLACE TO DELIVER MANAGEMENT TEAM BOARD Dr Paul D R MacLeman (CEO & MD) Graeme Kaufman (Chairman) Deb Cailes (Market Access) Dr Paul D R MacLeman (MD) Jane Kelly (Clinical) Geoff Lord (Vice Chairman) Paul Loria (Reg & Quality) Dr Graeme Blackman (NED) Joanna Johnson (CFO) Hugh B
Slide 16: Positioned to Deliver Financially
FINANCIALLY POSITIONED TO DELIVER FINANCIALS (ASX: IDT) MARKET CAP $73.5m (13Apr16) FY2014 FY2015 1H FY2016 REVENUE $13.4m $15.7m $6.5m EARNINGS AFTER ($6.6m) ($3.0m) ($3.5m) TAX NET ASSETS $25.5m $39.2m $43.7m CAPITAL STRUCTURE CASH $2.40 $0.13 $4.90 DEBT* $0.1m $0.0m $0.0m SHARES ON ISSUE 219.4M *
Slide 17: 2016 Milestones Target
TARGET 2016 MILESTONES INCREASED ORGANIC SALES TOWARDS PROFITABILITY PROGRESS TEMOZOLOMIDE TO COMMERCIAL LAUNCH MOVEMENT OF AN ADDITIONAL INTERNAL PRODUCT TOWARDS MARKET PROGRESS WITH RE-COMMERCIALISATION OF US GENERIC PORTFOLIO ACROSS MULTIPLE SITES MOVE FROM SERVICE PROVIDER, TOWARDS SPECIALTY GEN
Slide 18: Contact Us
CONTACT US Dr Paul D R MacLeman MANAGING DIRECTOR +61 (0) 3 9801 8888 info@idtaus.com.au www.idtaus.com.au www.idtaus.com.au 18
Slide 19: Questions and Answers
QUESTIONS AND ANSWERS